These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36150356)

  • 1. How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists' decisions to dispense opioids? A randomised controlled factorial experiment.
    Picco L; Sanfilippo P; Xia T; Lam T; Nielsen S
    Int J Drug Policy; 2022 Nov; 109():103856. PubMed ID: 36150356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical decision making involving prescription drug monitoring programs: A factorial, vignette-based study among student pharmacists.
    Tata V; Varisco TJ; Du N; Nguyen J; Haghparast P; Thornton JD
    J Am Pharm Assoc (2003); 2021; 61(3):316-324. PubMed ID: 33579594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists.
    Picco L; Lam T; Xia T; Nielsen S
    Int J Clin Pharm; 2023 Apr; 45(2):421-429. PubMed ID: 36528707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
    Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
    Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes.
    Nielsen S; Picco L; Russell G; Pearce C; Andrew NE; Lubman DI; Bell JS; Buchbinder R; Xia T
    Int J Drug Policy; 2023 Jul; 117():104053. PubMed ID: 37209441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment.
    Norwood CW; Wright ER
    Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Prescription-Opioid-Related Risks Using Prescription Drug Monitoring Programs' Algorithms and Clinical Screening Tools.
    Picco L; Jung M; Cangadis-Douglass H; Lam T; Nielsen S
    Pharmacy (Basel); 2023 Oct; 11(5):. PubMed ID: 37888509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers.
    Deyo RA; Hallvik SE; Hildebran C; Marino M; Springer R; Irvine JM; O'Kane N; Van Otterloo J; Wright DA; Leichtling G; Millet LM; Carson J; Wakeland W; McCarty D
    J Pain; 2018 Feb; 19(2):166-177. PubMed ID: 29054493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines.
    Manders L; Abd-Elsayed A
    Pain Physician; 2020 Jun; 23(3):299-304. PubMed ID: 32517396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of pharmacists' likelihood to query prescription drug monitoring program databases.
    Arnold A; Bentley JP; Patel A; Holmes E
    J Am Pharm Assoc (2003); 2021; 61(5):614-622.e3. PubMed ID: 33994328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
    Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
    J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key considerations for the implementation of clinically focused Prescription Drug Monitoring Programs to avoid unintended consequences.
    Haines S; Savic M; Nielsen S; Carter A
    Int J Drug Policy; 2022 Mar; 101():103549. PubMed ID: 34920217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of Electronic Health Record Integration and Clinical Decision Support to Improve Emergency Department Prescription Drug Monitoring Program Use.
    Hoppe JA; Ledbetter C; Tolle H; Heard K
    Ann Emerg Med; 2024 Jan; 83(1):3-13. PubMed ID: 37632496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions.
    Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S
    J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing community pharmacists' likelihood to ask medication monitoring questions: A factorial survey.
    Witry MJ; Doucette WR
    Res Social Adm Pharm; 2015; 11(5):639-50. PubMed ID: 25573019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription Drug Monitoring Programs and Pharmacist Orientation Toward Dispensing Controlled Substances.
    Fendrich M; Bryan JK; Hooyer K
    Subst Use Misuse; 2018 Jul; 53(8):1324-1330. PubMed ID: 29297725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription drug monitoring programs in community pharmacy: An exploration of pharmacist time requirements and labor cost.
    Upton C; Gernant SA; Rickles NM
    J Am Pharm Assoc (2003); 2020; 60(6):943-950. PubMed ID: 32792293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription drug monitoring programs and drug overdose deaths involving benzodiazepines and prescription opioids.
    Liang D; Shi Y
    Drug Alcohol Rev; 2019 Jul; 38(5):494-502. PubMed ID: 31317593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances.
    Fass JA; Hardigan PC
    J Manag Care Pharm; 2011; 17(6):430-8. PubMed ID: 21787028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacists' Perspectives on Practice, Availability, and Barriers Related to Opioids in Georgia.
    Lal A; Bai J; Basri D; Yeager KA
    Am J Hosp Palliat Care; 2019 Jun; 36(6):472-477. PubMed ID: 30522338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.